Page 61 - ITPS-8-3

INNOSC Theranostics and
Pharmacological Sciences Precision medicine and beyond in oncology

checkpoint inhibitors in microsatellite unstable/mismatch tumour mutational burden with outcomes in patients with
repair-deficient advanced pancreatic adenocarcinoma: An advanced solid tumours treated with pembrolizumab:
AGEO European Cohort. Eur J Cancer. 2023;188:90-97. Prospective biomarker analysis of the multicohort,
open-label, phase 2 KEYNOTE-158 study. Lancet Oncol.
doi: 10.1016/j.ejca.2023.04.012
2020;21(10):1353-1365.
82. Yang X, Yang C, Zhang S, et al. Precision treatment
in advanced hepatocellular carcinoma. Cancer Cell. doi: 10.1016/s1470-2045(20)30445-9
2024;42(2):180-197. 92. Zhang L, Xu J, Zhou S, et al. Endothelial DGKG promotes
tumor angiogenesis and immune evasion in hepatocellular
doi: 10.1016/j.ccell.2024.01.007
carcinoma. J Hepatol. 2024;80(1):82-98.
83. Ikeda M, Morizane C, Ueno M, Okusaka T, Ishii H,
Furuse J. Systemic therapy for hepatocellular carcinoma, doi: 10.1016/j.jhep.2023.10.006
from the early to the advanced stage: A Japanese perspective. 93. Aglietta M, Barone C, Sawyer MB, et al. A phase I
Jpn J Clin Oncol. 2025;55:465-476. dose escalation trial of tremelimumab (CP-675,206) in
combination with gemcitabine in chemotherapy-naive
doi: 10.1093/jjco/hyaf017
patients with metastatic pancreatic cancer. Ann Oncol.
84. Cheng SL, Wu CH, Tsai YJ, et al. CXCR4 antagonist-loaded 2014;25(9):1750-1755.
nanoparticles reprogram the tumor microenvironment
and enhance immunotherapy in hepatocellular carcinoma. doi: 10.1093/annonc/mdu205
J Control Release. 2025;379:967-981. 94. O’Reilly EM, Oh DY, Dhani N, et al. Durvalumab with
or without tremelimumab for patients with metastatic
doi: 10.1016/j.jconrel.2025.01.066
pancreatic ductal adenocarcinoma: A phase 2 randomized
85. Weiss GJ, Blaydorn L, Beck J, et al. Phase Ib/II study clinical trial. JAMA Oncol. 2019;5(10):1431-1438.
of gemcitabine, nab-paclitaxel, and pembrolizumab in doi: 10.1001/jamaoncol.2019.1588
metastatic pancreatic adenocarcinoma. Invest New Drugs.
2018;36(1):96-102. 95. Wu AA, Bever KM, Ho WJ, et al. A phase II study of allogeneic
GM-CSF-transfected pancreatic tumor vaccine (GVAX)
doi: 10.1007/s10637-017-0525-1
with ipilimumab as maintenance treatment for metastatic
86. Yang C, Zhang H, Zhang L, et al. Evolving therapeutic pancreatic cancer. Clin Cancer Res. 2020;26(19):5129-5139.
landscape of advanced hepatocellular carcinoma. Nat Rev
Gastroenterol Hepatol. 2023;20(4):203-222. doi: 10.1158/1078-0432.Ccr-20-1025
96. van den Eertwegh AJM, Versluis J, van den Berg HP, et al.
doi: 10.1038/s41575-022-00704-9
Combined immunotherapy with granulocyte-macrophage
87. Zhu AX, Abbas AR, de Galarreta MR, et al. Molecular colony-stimulating factor-transduced allogeneic prostate
correlates of clinical response and resistance to atezolizumab cancer cells and ipilimumab in patients with metastatic
in combination with bevacizumab in advanced castration-resistant prostate cancer: A phase 1 dose-
hepatocellular carcinoma. Nat Med. 2022;28(8):1599-1611. escalation trial. Lancet Oncol. 2012;13(5):509-517.
doi: 10.1038/s41591-022-01868-2 doi: 10.1016/S1470-2045(12)70007-4
88. Chen X, Xu H, Chen X, et al. First-line camrelizumab (a 97. Watson MM, Lea D, Gudlaugsson E, Skaland I, Hagland HR,
PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) Søreide K. Prevalence of PD-L1 expression is associated
and chemotherapy for advanced gastric cancer (SPACE): with EMAST, density of peritumoral T-cells and recurrence-
A phase 1 study. Signal Transduct Target Ther. 2024;9(1):73. free survival in operable non-metastatic colorectal cancer.
Cancer Immunol Immunother. 2020;69(8):1627-1637.
doi: 10.1038/s41392-024-01773-9
doi: 10.1007/s00262-020-02573-0
89. Ren Z, Xu J, Bai Y, et al. Sintilimab plus a bevacizumab
biosimilar (IBI305) versus sorafenib in unresectable 98. Yu W, Tao Q, Zhang Y, Yi F, Feng L. Efficacy and safety of
hepatocellular carcinoma (ORIENT-32): A randomised, regorafenib combined with toripalimab in the third-line and
open-label, phase 2-3 study. Lancet Oncol. beyond treatment of advanced colorectal cancer. J Oncol.
2021;22(7):977-990. 2021;2021:9959946.
doi: 10.1016/s1470-2045(21)00252-7 doi: 10.1155/2021/9959946
90. Sha D, Jin Z, Budczies J, Kluck K, Stenzinger A, Sinicrope FA. 99. Zhang C, Wang Z, Yang Z, et al. Phase I escalating-dose trial
Tumor mutational burden as a predictive biomarker in solid of CAR-T therapy targeting CEA(+) metastatic colorectal
tumors. Cancer Discov. 2020;10(12):1808-1825. cancers. Mol Ther. 2017;25(5):1248-1258.
doi: 10.1158/2159-8290.Cd-20-0522 doi: 10.1016/j.ymthe.2017.03.010
91. Marabelle A, Fakih M, Lopez J, et al. Association of 100. Ouladan S, Orouji E. Chimeric antigen receptor-T cells in

Volume 8 Issue 3 (2025) 55 doi: 10.36922/ITPS025140018